TB-500 Research: What the Studies Show
A study-by-study look at the TB-500 and Thymosin Beta-4 literature — the dermal wound-healing work, the phase 1 human safety trial, how the fragment is metabolised, and where the evidence runs out.
Mechanism of action
TB-500 is a synthetic seven-amino-acid peptide (LKKTETQ) taken from the naturally occurring parent protein Thymosin Beta-4 (Tβ4). Because that fragment isolates Tβ4's primary actin-binding domain, most of the peer-reviewed literature studies Tβ4 and infers TB-500's mechanism from it.
The described pathways are actin sequestration and cytoskeletal remodelling, endothelial cell migration and angiogenesis, recruitment of local progenitor cells to injury sites, and down-regulation of inflammatory and apoptotic signalling.
There are no broad human clinical trials of TB-500 itself in musculoskeletal applications. The evidence base is pre-clinical, animal and in-vitro work, plus human data on Tβ4 that is concentrated in skin and eye settings.
The studies
The design line on each card names the model, species and sample size, and states whether the compound tested was TB-500 itself or the full-length Thymosin Beta-4 parent protein.
Structural discovery & dermal efficacy
Thymosin beta-4 accelerates wound healing (Malinda et al.)
Whether Thymosin Beta-4 drives endothelial cell migration and speeds closure of full-thickness dermal wounds.
Human umbilical vein endothelial cell migration assays plus full-thickness rat and mouse dermal wound models · re-epithelialisation, collagen organisation and cell migration endpoints
- +42%
- Re-epithelialisation, day 4
- +61%
- Re-epithelialisation, day 7
- Stimulated
- Endothelial cell migration
- The foundational paper for the whole repair literature — it links a cell-level effect (endothelial migration) to a tissue-level outcome (faster closure) in the same work.
- Collagen organisation at the wound site improved alongside the closure rate, not just wound size.
- Tested the full-length Tβ4 protein rather than the TB-500 fragment.
Human safety & tolerability
Randomised, placebo-controlled intravenous Tβ4 in healthy volunteers (Crockford et al.)
Safety, tolerability and pharmacokinetics of synthetic Thymosin Beta-4 given intravenously to healthy adults.
Randomised, placebo-controlled single- and multiple-dose phase 1 trial · healthy volunteer cohorts · escalating daily intravenous doses from 42 mg to 1260 mg over 14 days
- 42-1260 mg IV
- Dose range
- 0
- Serious adverse events
- None
- Dose-limiting toxicities
- The strongest human data point in this literature: a properly randomised, placebo-controlled safety trial, not an observational series.
- It measured safety and pharmacokinetics only — it was not designed to show whether the peptide repairs anything.
- The compound tested was full-length synthetic Tβ4 given intravenously, so it does not directly establish safety for the TB-500 fragment by another route.
Multi-system regenerative performance
Regenerative Tβ4 accelerates dermal healing across animal models and patients (Kleinman & Goldstein)
Pulling together how the peptide acts on inflammation, cell death, stem-cell recruitment and scarring.
Review of pre-clinical animal models — including diabetic and aged animals — alongside patient data · inflammation, apoptosis, progenitor migration and myofibroblast endpoints
- Down-regulated
- Acute inflammation
- Reduced
- Apoptotic cell death
- Decreased
- Scar-forming myofibroblasts
- Effects persisted in impaired-healing models (diabetic and aged animals), which is where most wound-repair candidates fail.
- Less scarring alongside faster closure is the finding that distinguishes this peptide from simple growth-factor acceleration.
- A synthesis of existing work rather than new experimental data, so it inherits the limitations of its sources.
Metabolism & cleavage of the TB-500 fragment
Quantification of TB-500 and its metabolites in vitro and in rats (Choi et al.)
What happens to the TB-500 fragment itself once it is in serum and in a living animal.
UHPLC-Q-Exactive Orbitrap MS/MS analysis · human serum incubation and rat in-vivo sampling · parent peptide and metabolite quantification over time
- Serial C-terminal cleavage
- Degradation pattern
- Ac-LKKTET, Ac-LK
- Key metabolites
- TB-500 itself
- Compound tested
- One of the few studies that tests the TB-500 fragment directly rather than the parent protein.
- The downstream metabolites appear to carry the wound-healing activity, which reframes the parent fragment as a precursor rather than the active species.
- It also gives analytical labs a validated screening method for detecting TB-500 and its breakdown products.
Comprehensive evidence mapping
Tβ4 and TB-500 in tissue healing, regeneration and musculoskeletal repair (scoping review)
Mapping the whole evidence base to see which repair claims are actually supported and where the gaps are.
Scoping review · 80 eligible studies mapped across wound, vascular, corneal and musculoskeletal repair categories
- 80
- Studies mapped
- Wound, vascular, corneal
- Best-supported areas
- Sparse
- Human musculoskeletal evidence
- Repair effects are consistent and well documented in skin, vascular and corneal settings.
- Human evidence is concentrated in ocular and skin work; direct TB-500 clinical musculoskeletal evidence is the clear gap.
- The most common use case people are interested in — tendon, muscle and joint recovery — is the one with the least human support.
Storage & handling
TB-500 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.